Johnson & Johnson Enters the Robotic Surgery Arena
Johnson & Johnson has officially entered the competitive robotic surgery market following the FDA approval of its Ottava system this summer. The healthcare giant intends to challenge the long-standing dominance of Intuitive Surgical, the company behind the da Vinci system. While Intuitive Surgical has held a significant head start for over two decades, J&J management views its new entrant as a critical component of its future growth strategy within the medical technology sector. Surgical procedures currently represent the largest portion of the company's MedTech business, and this new technology arrives as J&J moves to divest its slower-growing orthopedic assets.
Market data underscores the potential stakes. Precedence Research estimates the U.S. surgical robotics market will grow from $4.4 billion in 2025 to $18.75 billion by 2035. Globally, the industry is expected to reach $50.29 billion within the same timeframe. Hani Abouhalka, who leads J&J’s surgery and robotics unit, noted the company’s intent to become a major force in this field. With less than a quarter of U.S. surgeries currently performed with robotic assistance, there remains significant room for expansion.
Designing for a Modern Operating Room
The Ottava system features a design that integrates robotic arms directly into the operating table. This configuration marks a departure from existing systems that require external, mobile carts to be wheeled into surgical suites. J&J claims this design occupies 30% to 50% less space than traditional alternatives. Such efficiency could allow hospitals to adopt robotic programs without undertaking costly renovations to their existing infrastructure.
Beyond space considerations, J&J intends to leverage its long-standing relationships with hospital systems. The company already supplies a wide array of surgical tools, including staplers and energy devices. Dr. Jacob Greenberg, a consultant for J&J and associate professor of surgery at Duke University, suggests that bundling Ottava with these existing supply lines could drive hospital adoption through cost reductions. The company plans to take a disciplined approach, rolling out the system to select locations before scaling up to broader availability in Western Europe and Japan.
The Competitive Landscape and Market Skepticism
Intuitive Surgical maintains a substantial lead with over 11,700 systems installed globally. The company operates on a model that emphasizes recurring revenue from specialized instruments and accessories, which account for roughly 60% of its total sales. Additionally, Medtronic provides a competing presence with its Hugo system, which received FDA clearance in late 2025. Medtronic expects to have 250 Hugo units installed by the end of 2026, highlighting the scale of the challenge facing new market participants.
Wall Street analysts maintain varied perspectives on the outlook for Ottava. Some observers point to potential workflow challenges related to sterilization and limited initial production capacity as reasons to temper immediate expectations. Analysts at Oppenheimer recently raised their rating on Intuitive Surgical, describing the current competitive landscape as a non-factor for the established leader. Still, others like those at UBS remain optimistic, suggesting that even a gradual rollout could provide upside to J&J’s MedTech growth targets.
Looking Toward Long-Term Growth
J&J executives describe Ottava as one of the most significant innovations the firm will bring to market this decade. While the financial impact will likely remain minimal in the short term, the company insists that the program will become materially significant by 2030. The broader MedTech division expects its focus to narrow to surgery, cardiovascular health, and vision following the exit from the orthopedic space. This pivot aims to prioritize higher-margin markets and provide a clearer path for revenue expansion.
Investors are watching for specific metrics as the launch unfolds. Future reports will need to detail the number of units placed, surgeon utilization rates, and the progress of additional regulatory approvals for new procedures. As the hospital sales cycle is notoriously long, the true influence of Ottava on J&J’s bottom line will take several years to fully materialize. The company remains committed to the project as a foundation for its leadership in the surgical field for years to come.